325 related articles for article (PubMed ID: 24102067)
21. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
[TBL] [Abstract][Full Text] [Related]
22. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
Basile EM; Tolomeo D; Gluck E
Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
[TBL] [Abstract][Full Text] [Related]
23. The analysis of the market success of FDA approvals by probing top 100 bestselling drugs.
Polanski J; Bogocz J; Tkocz A
J Comput Aided Mol Des; 2016 May; 30(5):381-9. PubMed ID: 27125384
[TBL] [Abstract][Full Text] [Related]
24. International Conference on Harmonisation; Guidance on S9 Nonclincal Evaluation for Anticancer Pharmaceuticals; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2010 Mar; 75(44):10487-8. PubMed ID: 20383918
[TBL] [Abstract][Full Text] [Related]
25. Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans.
Piana C; Kliphuis E; Della Pasqua O
Clin Trials; 2013 Apr; 10(2):269-79. PubMed ID: 23335676
[TBL] [Abstract][Full Text] [Related]
26. The opportunities of mining historical and collective data in drug discovery.
Wassermann AM; Lounkine E; Davies JW; Glick M; Camargo LM
Drug Discov Today; 2015 Apr; 20(4):422-34. PubMed ID: 25463034
[TBL] [Abstract][Full Text] [Related]
27. International Conference on Harmonisation; guidance on S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals intended for Human Use; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2012 Jun; 77(110):33748-9. PubMed ID: 22675782
[TBL] [Abstract][Full Text] [Related]
28. Fluorine-Containing Drugs Approved by the FDA in 2018.
Mei H; Han J; Fustero S; Medio-Simon M; Sedgwick DM; Santi C; Ruzziconi R; Soloshonok VA
Chemistry; 2019 Sep; 25(51):11797-11819. PubMed ID: 31099931
[TBL] [Abstract][Full Text] [Related]
29. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
[TBL] [Abstract][Full Text] [Related]
30. International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2010 Jan; 75(13):3471-2. PubMed ID: 20349552
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in fluorination techniques and their anticipated impact on drug metabolism and toxicity.
Murphy CD; Sandford G
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):589-99. PubMed ID: 25728479
[TBL] [Abstract][Full Text] [Related]
32. Official USP Reference Standards: metrology concepts, overview, and scientific issues and opportunities.
Williams RL; ;
J Pharm Biomed Anal; 2006 Jan; 40(1):3-15. PubMed ID: 16303277
[TBL] [Abstract][Full Text] [Related]
33. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review.
Tyner K; Sadrieh N
Methods Mol Biol; 2011; 697():17-31. PubMed ID: 21116951
[TBL] [Abstract][Full Text] [Related]
34. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
Xu K; Coté TR
Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
[TBL] [Abstract][Full Text] [Related]
35. ICH S9: Developing anticancer drugs, one year later.
Ponce R
Toxicol Pathol; 2011 Oct; 39(6):913-5. PubMed ID: 21859887
[TBL] [Abstract][Full Text] [Related]
36. Trends in antimicrobial drug development: implications for the future.
Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
[TBL] [Abstract][Full Text] [Related]
37. International Conference on Harmonisation: guidance on testing for carcinogenicity of pharmaceuticals. Notice. Food and Drug Administration, HHS.
Fed Regist; 1998 Feb; 63(35):8983-6. PubMed ID: 12269370
[TBL] [Abstract][Full Text] [Related]
38. Applications of fluorine-containing amino acids for drug design.
Mei H; Han J; Klika KD; Izawa K; Sato T; Meanwell NA; Soloshonok VA
Eur J Med Chem; 2020 Jan; 186():111826. PubMed ID: 31740056
[TBL] [Abstract][Full Text] [Related]
39. Prospects for rapid advances in the development of new medicines for special medical needs.
Milne CP
Clin Pharmacol Ther; 2014 Jan; 95(1):98-109. PubMed ID: 23917473
[TBL] [Abstract][Full Text] [Related]
40. Natural products and Pharma 2011: strategic changes spur new opportunities.
Carter GT
Nat Prod Rep; 2011 Oct; 28(11):1783-9. PubMed ID: 21909580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
